

Survivorship

Survivorship protocols			
Study	Clinical trial name	Phase/type	Age
COG ALTE1621	ALTE1621, Pharmacologic Reversal of Ventricular Remodeling in Childhood Cancer Survivors at Risk for Heart Failure (PREVENT-HF): A Phase 2b Randomized Placebo-Controlled (Carvedilol) Trial https://clinicaltrials.gov/ct2/show/NCT02717507	IIb	<21 yr when cancer diagnosed
COG ALTE1631	ALTE1631, A Randomized Web-based Physical Activity Intervention among Children and Adolescents with Acute Lymphoblastic Leukemia https://clinicaltrials.gov/ct2/show/NCT03223753	NA	≥8 to ≤16 yr
COG ALTE03N1	Key Adverse Events after Childhood Cancer (cardiac, stroke, secondary malignancies)/ closed to AVN patients as of 11-26-08 https://clinicaltrials.gov/ct2/show/NCT00082745	Non-therapeutic	≤21 yr at dx
COG ALTE05N1	Umbrella Long-Term Follow-Up Protocol https://clinicaltrials.gov/ct2/show/NCT00736749	Non-therapeutic	Any age
COG ALTE11C2	ALTE11C2, Health Effects after Anthracycline and Radiation Therapy (HEART): Dexrazoxane and Prevention of Anthracycline-related Cardiomyopathy https://clinicaltrials.gov/ct2/show/NCT01790152	Non-therapeutic	Any age
COG ALTE15N2	ALTE15N2: LEAHRN (Late Effects After High-Risk Neuroblastoma) Study https://clinicaltrials.gov/ct2/show/NCT03057626	Non-therapeutic	≥5 yr
COG ALTE16C1	ALTE16C1: Effects of Modern Chemotherapy Regimens on Spermatogenesis and Steroidogenesis in Adolescent and Young Adult (AYA) Survivors of Osteosarcoma https://clinicaltrials.gov/ct2/show/NCT03206450	Non-therapeutic	Males ≥18 to ≤50 yr previously treated on AOST0331 or CCG7921 (INT0133, POG9351)
LETKI	LETKI: Late Effects after Tyrosine Kinase Inhibitor Therapy in Children and Adolescents	Non-therapeutic	≤21 yr
CCSS	Childhood Cancer Survivorship Study https://clinicaltrials.gov/ct2/show/NCT01120353	Non-therapeutic	Any age, but diagnosed at <21 yr

CAYACSS	Long-term Follow-up of Childhood, Adolescent, and Young Adult Cancer Survivors (CAYACSS)	Non-therapeutic	Any age but must be ≤ 30 yr at dx
Surv Engagement	CURE Patient Engagement: Evaluating Patient Engagement in Survivor Healthcare after Childhood Cancer Treatment <i>Aim 1: Parents/caregivers of ped survivors 1 to 17 yr off treatment for 12-18 mo</i> <i>Aim 2: Parents/caregivers of ped survivors <19 yr not seen in Surv Clinic in 3 yr, or those who have never been to Surv Clinic</i>	Non-therapeutic	[See col 2]
Surv Transition Predictors	Predictors of Successful Transition of Childhood Cancer Survivors	Non-therapeutic	20-30 yr
Surv Transfer Outcomes	Predicting Childhood Cancer Survivors' Transition Readiness & Transfer Outcomes	Non-therapeutic	18 to 25 yr
Surv E-Screen	Evaluating Electronic Psychosocial Screening in Pediatric Oncology	Non-therapeutic	≥ 2 yr
QOL Targeted Tx Brain Tumors	Health-related Quality of Life Outcomes during Molecularly Targeted Therapy for the Treatment of High Risk Pediatric Brain Tumors	Non-therapeutic	≤ 21 yr
CHOA AWAKE	Improving Health-promoting Behaviors in Adolescent Cancer Survivors using AWAKE: A Feasibility Trial	Non-Therapeutic	13 to 17 yr